FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895895963> ?p ?o ?g. }

• W2895895963 endingPage "e182355" @default.
• W2895895963 startingPage "e182355" @default.
• W2895895963 abstract "<h3>Importance</h3> No trials to date have demonstrated the benefits of tocolysis on death and/or neonatal morbidity in preterm infants; tocolytics may affect the fetal blood-brain barrier. <h3>Objectives</h3> To assess the risks associated with tocolysis in women delivering prematurely as measured by death and/or intraventricular hemorrhage (IVH) in preterm infants and to compare the association of calcium channel blockers (CCBs) nifedipine and nicardipine hydrochloride vs atosiban used for tocolysis with death and/or IVH. <h3>Design, Settings, and Participants</h3> The French 2011 EPIPAGE-2 (Enquête Épidémiologique sur les Petits Âges Gestationnels) cohort was limited to mothers admitted for preterm labor without fever, who delivered from 24 to 31 weeks of gestation from April 1 through December 31, 2011. Groups of preterm infants with vs without tocolytic exposure and groups with atosiban vs CCB exposure were compared. Data analysis was performed from June 7, 2014, through September 3, 2017. <h3>Exposures</h3> Tocolytics. <h3>Main Outcomes and Measures</h3> The primary outcome was a composite of death and/or IVH in preterm infants. Secondary outcomes included death, IVH, and a composite of death and/or grades III to IV IVH. <h3>Results</h3> A total of 1127 mothers (mean [SD] age, 25.5 [6.0] years) experienced preterm labor and gave birth to 1343 preterm infants with a male to female ratio of 1.23 and mean (SD) gestational age of 27 (2.5) weeks. Of these, 789 mothers (70.0%) received tocolytics; 314 (39.8%) received only atosiban, and 118 (15.0%) received only a CCB. In the first analysis, the primary outcome (death and/or IVH) was not significantly different in preterm infants with vs without tocolytic exposure (183 of 363 [50.4%] vs 207 of 363 [57.0%]; relative risk [RR], 0.88; 95% CI, 0.77-1.01;<i>P</i> = .07). The secondary outcome (death and/or grades III-IV IVH) was significantly lower in preterm infants with vs without tocolytic exposure (92 of 363 [25.3%] vs 118 of 363 [32.5%]; RR, 0.78; 95% CI, 0.62-0.98;<i>P</i> = .03). Other outcomes did not differ significantly. In the secondary analysis, death and/or IVH was not significantly different in preterm infants with atosiban vs CCB exposure (96 of 214 [44.9%] vs 62 of 121 [51.2%]; RR, 0.88; 95% CI, 0.70-1.10;<i>P</i> = .26), nor was IVH (77 of 197 [39.1%] vs 48 of 106 [45.3%]; RR, 0.86; 95% CI, 0.66-1.13;<i>P</i> = .29). <h3>Conclusions and Relevance</h3> In this population-based study, findings suggest that tocolytics were associated with a reduction of death and severe IVH. Other studies are necessary to compare perinatal outcomes after use of atosiban vs CCBs." @default.
• W2895895963 created "2018-10-26" @default.
• W2895895963 creator A5000577845 @default.
• W2895895963 creator A5017133797 @default.
• W2895895963 creator A5022386988 @default.
• W2895895963 creator A5023247351 @default.
• W2895895963 creator A5025600213 @default.
• W2895895963 creator A5036139228 @default.
• W2895895963 creator A5059256161 @default.
• W2895895963 creator A5063284947 @default.
• W2895895963 date "2018-09-21" @default.
• W2895895963 modified "2023-10-12" @default.
• W2895895963 title "Association of Intraventricular Hemorrhage and Death With Tocolytic Exposure in Preterm Infants" @default.
• W2895895963 cites W104991833 @default.
• W2895895963 cites W1900567827 @default.
• W2895895963 cites W1967339035 @default.
• W2895895963 cites W1969912564 @default.
• W2895895963 cites W1974604794 @default.
• W2895895963 cites W1981492357 @default.
• W2895895963 cites W1983569899 @default.
• W2895895963 cites W1989158466 @default.
• W2895895963 cites W1992969806 @default.
• W2895895963 cites W2002519037 @default.
• W2895895963 cites W2012257423 @default.
• W2895895963 cites W2025097421 @default.
• W2895895963 cites W2039403376 @default.
• W2895895963 cites W2046016307 @default.
• W2895895963 cites W2046224781 @default.
• W2895895963 cites W2052465889 @default.
• W2895895963 cites W2078700022 @default.
• W2895895963 cites W2082570078 @default.
• W2895895963 cites W2103649926 @default.
• W2895895963 cites W2150291618 @default.
• W2895895963 cites W2164028065 @default.
• W2895895963 cites W2290577724 @default.
• W2895895963 cites W2346410088 @default.
• W2895895963 cites W2545445396 @default.
• W2895895963 cites W2566914768 @default.
• W2895895963 cites W2573522463 @default.
• W2895895963 cites W2599076725 @default.
• W2895895963 cites W2609840075 @default.
• W2895895963 cites W4230239216 @default.
• W2895895963 cites W4292229870 @default.
• W2895895963 cites W4387072861 @default.
• W2895895963 doi "https://doi.org/10.1001/jamanetworkopen.2018.2355" @default.
• W2895895963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324618" @default.
• W2895895963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30646165" @default.
• W2895895963 hasPublicationYear "2018" @default.
• W2895895963 type Work @default.
• W2895895963 sameAs 2895895963 @default.
• W2895895963 citedByCount "11" @default.
• W2895895963 countsByYear W28958959632019 @default.
• W2895895963 countsByYear W28958959632020 @default.
• W2895895963 countsByYear W28958959632021 @default.
• W2895895963 countsByYear W28958959632022 @default.
• W2895895963 countsByYear W28958959632023 @default.
• W2895895963 crossrefType "journal-article" @default.
• W2895895963 hasAuthorship W2895895963A5000577845 @default.
• W2895895963 hasAuthorship W2895895963A5017133797 @default.
• W2895895963 hasAuthorship W2895895963A5022386988 @default.
• W2895895963 hasAuthorship W2895895963A5023247351 @default.
• W2895895963 hasAuthorship W2895895963A5025600213 @default.
• W2895895963 hasAuthorship W2895895963A5036139228 @default.
• W2895895963 hasAuthorship W2895895963A5059256161 @default.
• W2895895963 hasAuthorship W2895895963A5063284947 @default.
• W2895895963 hasBestOaLocation W28958959631 @default.
• W2895895963 hasConcept C126322002 @default.
• W2895895963 hasConcept C131872663 @default.
• W2895895963 hasConcept C187212893 @default.
• W2895895963 hasConcept C2777407796 @default.
• W2895895963 hasConcept C2778376644 @default.
• W2895895963 hasConcept C2779066535 @default.
• W2895895963 hasConcept C2779234561 @default.
• W2895895963 hasConcept C2779252433 @default.
• W2895895963 hasConcept C2780931799 @default.
• W2895895963 hasConcept C2908881489 @default.
• W2895895963 hasConcept C3019152611 @default.
• W2895895963 hasConcept C46973012 @default.
• W2895895963 hasConcept C519063684 @default.
• W2895895963 hasConcept C54355233 @default.
• W2895895963 hasConcept C71924100 @default.
• W2895895963 hasConcept C86803240 @default.
• W2895895963 hasConceptScore W2895895963C126322002 @default.
• W2895895963 hasConceptScore W2895895963C131872663 @default.
• W2895895963 hasConceptScore W2895895963C187212893 @default.
• W2895895963 hasConceptScore W2895895963C2777407796 @default.
• W2895895963 hasConceptScore W2895895963C2778376644 @default.
• W2895895963 hasConceptScore W2895895963C2779066535 @default.
• W2895895963 hasConceptScore W2895895963C2779234561 @default.
• W2895895963 hasConceptScore W2895895963C2779252433 @default.
• W2895895963 hasConceptScore W2895895963C2780931799 @default.
• W2895895963 hasConceptScore W2895895963C2908881489 @default.
• W2895895963 hasConceptScore W2895895963C3019152611 @default.
• W2895895963 hasConceptScore W2895895963C46973012 @default.
• W2895895963 hasConceptScore W2895895963C519063684 @default.
• W2895895963 hasConceptScore W2895895963C54355233 @default.
• W2895895963 hasConceptScore W2895895963C71924100 @default.
• W2895895963 hasConceptScore W2895895963C86803240 @default.

• next